Namenda to Prevent Post-Operative Delirium

Stopped early · Phase 4

Conditions studied: Delirium, Post-Operative States

In brief

Post Operative Delirium is a common and serious risk of surgery. Delirium, when it occurs is associated with an increased risk of mortality, increase length of stay, and more adverse outcomes in general, including increased risk of higher level of care required at discharge. Namenda, which is currently approved for moderate or severe Alzheimer's disease has a unique mechanism of action than other drugs for this condition. It may have the ability to protect the brain from more severe consequences of hypoxia, or hypoglycemia. Hence it is being looked at in this study to see if it can reduce the incidence and/or severity of delirium post-operatively.

Key facts

Study ID

NCT00303433

Run by

University of Rochester

People needed

30

Starts

2006-03-01

Expected to finish

2006-09-01

Last updated by the study team

2015-06-03

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Medically stable
• 50 years of age or older
• having elective joint replacement surgery or other orthopedic procedures that are major surgery and require general anesthesia.

You may not qualify if…

• Alcohol or sedative hypnotic abuse or dependence
• Pregnancy
• Dementia or MR/DD patients if they do not have sufficient capacity to understand the consent
• renal impairment or a creatinine of 1.4 or higher
• currently taking cholinesterase inhibitors.

Where it is running

• University of Rochester Medical Center — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.